If you have tried to renew a Wegovy savings card in the last few months, you have probably noticed the offer is not what it was. The "pay as little as $0" language has narrowed. The uninsured discount has thinned. The whole program feels like it is being quietly wound down. It is — and that is the least surprising thing that could possibly happen.
I want to argue against the two explanations you will hear most. This is not Novo Nordisk being cheap, and it is not a billing glitch that a call to the pharmacy will fix. The Wegovy savings card is thinning out because the strategic job it was built to do is finished.
My thesis is blunt: a copay card is a customer-acquisition weapon, not a charity. It made sense only while three conditions held at once — Wegovy was scarce, insurance was hostile, and Novo needed to buy patient trial and lock in adherence before a competitor got there first. All three have flipped inside eighteen months. The card is being retired the way any acquisition subsidy is retired once the market is won: quietly, and replaced by a flat cash price the company would much rather you look at instead.
The basics, briefly. Wegovy is Novo Nordisk's brand of semaglutide 2.4 mg, the weekly obesity injection the FDA approved in June 2021. Its list price sits around $1,349 for a 28-day supply. Against a number that large, the savings card was never a rounding error — for commercially insured patients it could drop the monthly cost to as little as $0, and for the uninsured it once knocked a few hundred dollars off the cash price. That gap between $1,349 and near-zero is the entire story, because someone was always paying to close it.
What a savings card actually is
Strip away the friendly branding and a copay card is a targeted price discount that the manufacturer pays for, aimed at exactly one type of buyer: the commercially insured patient whose plan technically covers the drug but saddles them with a copay high enough to make them abandon the prescription. The card eats that copay so the patient fills, and keeps filling.
Two structural facts about these cards matter here. First, by federal law they cannot be used by anyone on Medicare or Medicaid — the anti-kickback statute treats a manufacturer subsidy on a government-reimbursed drug as an illegal inducement. So the card was never a mass-market tool; it only ever reached the commercially insured slice. Second, a card is pure customer-acquisition cost. Novo spends real money on every fill to buy a habit — the weekly injection, the titration schedule, the identity of being "a Wegovy patient." You do not spend that money forever. You spend it until the customer is yours, then you stop.
Read that way, the interesting question is not "why is the card shrinking now." It is "what changed that made Novo comfortable letting it shrink." Three things did.
Condition one: the scarcity is gone
For most of 2022 through 2024, Wegovy lived on the FDA shortage list. When you cannot make enough of a product, subsidizing demand is close to insane — you are paying to create want you cannot satisfy, and every discounted patient you win is a patient you then fail. Novo ran the card anyway, because the card was defensive: it was buying loyalty ahead of the tsunami of competition and compounded copies it knew was coming.
By late 2024 the FDA declared the semaglutide shortage resolved, and by 2025 Novo was manufacturing at a scale that could actually meet demand. The moment supply caught up, the entire logic of a demand subsidy inverted. Now every dollar of copay assistance is a dollar spent stimulating demand for a product you can finally sell at full margin. The card stopped being defense and became pure cost.
Condition two: coverage stopped being the bottleneck
The card existed to paper over hostile insurance. That hostility is easing at the exact wrong moment for the card's survival. In March 2024 the FDA approved Wegovy to cut the risk of major cardiovascular events in overweight and obese adults with established heart disease, on the strength of the SELECT trial, which reported a roughly 20% reduction in heart attack, stroke, and cardiovascular death.
That approval did something no marketing budget could: it cracked open Medicare Part D. Medicare is statutorily barred from covering drugs used purely for weight loss, but a cardiovascular indication is a different animal, and plans began covering Wegovy for the SELECT population through 2024 and 2025. When a drug earns real medical coverage on its own merits, the manufacturer no longer needs to bribe the copay down to keep patients on it. The clinical data did the job the card used to do.
The disappearing discount is not a company getting stingier. It is a company that no longer needs to pay you to try a product you now come looking for.
Condition three: Novo built a channel that makes the card redundant
This is the part I think is most underrated. In March 2025 Novo launched NovoCare Pharmacy, a direct-to-patient channel selling all doses of Wegovy for cash at a flat $499 a month for people without coverage. That number is not a coincidence — it is a straight answer to LillyDirect, which had put cash-pay Zepbound at the same $499, a strategy this magazine has already decoded.
Look at what $499 does to the savings card. The card's whole purpose for the uninsured was to shave a chaotic $1,349 sticker down to something a cash payer might stomach. A flat $499 direct channel does that permanently, transparently, and without the paperwork, expiration dates, or annual benefit caps that made cards so slippery. Once you have a clean $499 cash price, a messy uninsured discount card is redundant infrastructure. You retire it. What looks to the patient like losing a discount is, from Novo's side, replacing a complicated subsidy with a simpler, lower, more durable price.
The case that I'm reading strategy into plain cost-cutting
The honest counter-argument: maybe I'm over-reading this. Maybe Novo is simply trimming a program that got expensive as volume exploded, and there is no elegant three-condition logic — just a finance team looking at a copay-assistance line that ballooned with every new prescription and deciding to cap it. Programs get cut because they cost money. Sometimes that is the whole story.
I take that seriously, and I think it is partly true — the card did get expensive, precisely because it worked. But "it got expensive" and "its strategic job is done" are the same observation from two angles. A subsidy that scales linearly with success is one you can only afford while you still need it to win share. The tell is not that Novo is cutting a cost. The tell is that it is cutting this cost now, at the exact moment supply, coverage, and a direct $499 channel each independently reduce how much the card buys. When three separate forces all point the same way, "they just wanted to save money" is the shallow reading, not the deep one.
What the vanishing card actually tells you
Step back and the shrinking discount reads as a status signal about the whole obesity-drug market. Copay cards are a scarcity-and-acquisition tool. They flourish when a product is fighting for adoption against skeptical payers and thin supply. They wither when the product wins — when supply is abundant, coverage arrives on clinical merit, and the manufacturer can sell direct at a price it sets. Wegovy has crossed that line. The disappearing card is the market telling you the launch phase is over and the franchise phase has begun.
So when you read "Wegovy savings cards are getting harder to find," resist the reflex to call it corporate meanness. It is the opposite of a company in trouble. It is a company that no longer has to pay you to try a drug you now come looking for, that has coverage doing its persuading, and that would prefer you simply look at a flat $499 than chase a discount it no longer needs to offer. That is not stinginess. That is what winning looks like from the inside — and it is the most honest read of where this market has actually gone.
Ozemback — July 2026